Eczema drug dosing could be cut back, new trial hopes

NCT ID NCT06004986

Recruiting now Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adults with well-controlled eczema can safely extend the time between doses of the drug Dupilumab (Dupixent). 216 participants will be randomly assigned to receive the drug every 2, 3, or 4 weeks. Researchers will compare eczema severity and quality of life across the groups to see if less frequent dosing works just as well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab (Dupixent)
What this could lead to: If successful, this could show that many patients can take Dupilumab less often, reducing treatment burden and cost while still controlling eczema.
What could go wrong: This is a Phase 4 trial with only 216 participants, so results may not apply to everyone. Some patients might see their eczema worsen with longer intervals between doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ATOPIC DERMATITIS ECZEMA

Contacts and locations

Locations

Amsterdam University Medical Centers
RECRUITING

Amsterdam, North Holland, 1105 AZ, Netherlands
Erasmus Medical Center
NOT_YET_RECRUITING

Rotterdam, South Holland, 3015 GD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.